A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

Management of rheumatoid arthritis: the 2012 perspective

(2014) Hisashi Yamanaka et al.   Modern Rheumatology

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

(2012) Timothy P. LaBranche et al.   ARTHRITIS AND RHEUMATISM

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

(2012) Pankaj Gupta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

(2012) Kris Vaddi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

(2012) Peter Norman   EXPERT OPINION ON THERAPEUTIC PATENTS

Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis

(2012) David A. Fox   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

(2011) Sanna Rosengren et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells

(2011) Keisuke Maeshima et al.   ARTHRITIS AND RHEUMATISM

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical safety of tocilizumab in rheumatoid arthritis

(2010) Bernard Bannwarth et al.   Expert Opinion On Drug Safety

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

(2010) Mark E. Flanagan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

(2009) J H Coombs et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

(2009) Stanley Cohen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of CP-690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers

(2009) Nervin Lawendy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rheumatoid arthritis

(2009) Lars Klareskog et al.   LANCET

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

(2008) Anthony J Milici et al.   ARTHRITIS RESEARCH & THERAPY